View More View Less
  • 1 Pest Megyei Flór Ferenc Kórház, Kardiometabolikus Centrum V. Belgyógyászat-Lipidológiai Osztály, Regionális Zsíranyagcsere-központ és Hypertonia Decentrum Kistarcsa Semmelweis tér 1. 2143
  • 2 Pest Megyei Flór Ferenc Kórház, Kardiometabolikus Centrum III. Belgyógyászat-Kardiológiai Osztály Kistarcsa
  • 3 Fővárosi Önkormányzat Szent Imre Kórház Kardiometabolikus Centrum, Lipid Profil Budapest
  • 4 Fővárosi Önkormányzat Szent Imre Kórház Főigazgatóság Budapest
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Az elhízás jelenleg az egyik legnagyobb egészségügyi probléma. A testtömegcsökkentés komplex tevékenység, amelybe beletartozik az életmód-változtatás (diéta+testmozgás), a viselkedésterápia, a különböző gyógyszerek alkalmazása és bizonyos esetben sebészeti beavatkozások. A diéta és a testmozgás a legjobb módszerek az elhízás kezelése és megelőzése során, azonban sok nehézséggel jár alkalmazásuk. Az elhízás gyógyszeres kezelése önmagában sokszor csak mérsékelt eredménnyel jár, a gyógyszerek alkalmazását a mellékhatások határolhatják be, abbahagyásukkor megáll a testtömegcsökkenés, és visszahízás következik be. A megfelelő eredmény érdekében kombinálnunk kell a különböző testtömegcsökkentő módszereket. Az elhízás kezelésére alkalmazott gyógyszerek számos hatástani csoportba tartozhatnak. Fokozhatják a telítettségérzést, csökkenthetik a tápanyag-felszívódást, növelhetik az anyagcserét, de hatásuk általában csak mérsékelt. Régebben számos készítményt alkalmaztak az elhízás gyógyszeres kezelésére, beleértve a pajzsmirigyhormont, a dinitrofenolt, az amfetamint és ezek analógjait, a fenfluramint stb. Jelenleg az elhízás kezelésének hosszú távú alkalmazására (≥24 hét) csak az orlistat elérhető, mivel a sibutramint és a rimonabantot egyaránt visszavonták a gyógyszerpiacról. Az elhízás kezelésére jelenleg is számos készítményt vizsgálnak, ezek közül az inkretintengelyre ható GLP-1-analóg liraglutid rendelkezik a legnagyobb eséllyel. Orv. Hetil., 2012, 153, 363–373.

  • Halmy, L., Simonyi, G., Csatai, T., et al.: Hungarian Policeman Study on the prevalence of obesity. Int. J. Obes. Rel. Met. Dis., 2003, 27 (Suppl. 1), 132.

    Csatai T. , 'Hungarian Policeman Study on the prevalence of obesity ' (2003 ) 27 Int. J. Obes. Rel. Met. Dis. : 132 -.

    • Search Google Scholar
  • Martos, É.: Measurement methods, international and domestic data. [Mérési módszerek, nemzetközi és hazai adatok.] In: Császár, A., Bedros, J. R., Simonyi, G., et al. (eds.). Obezitás. Elmélet és kinikum. Teva Magyarország Zrt., Budapest, 2010, 15–20. [Hungarian]

    Martos É. , '', in Obezitás. Elmélet és kinikum , (2010 ) -.

  • Kopelman, P. G.: Obesity as a medical problem. Nature, 2000, 404, 635–643.

    Kopelman P. G. , 'Obesity as a medical problem ' (2000 ) 404 Nature : 635 -643.

  • Haslam, D. W., James, W. P.: Obesity. Lancet, 2005, 366, 1197–1209.

    James W. P. , 'Obesity ' (2005 ) 366 Lancet : 1197 -1209.

  • Szollár, L., Pados, Gy., Romics, L., et al.: Summary of recommendations of the 4th Hungarian Cardiovascular Consensus Conference. [Összefoglalás a IV. Magyar Kardiovaszkuláris Konszenzus Konferencia ajánlásairól.]. Metabolizmus, 2010, 8 (Suppl. A), 9–12. [Hungarian]

    Romics L. , 'Summary of recommendations of the 4th Hungarian Cardiovascular Consensus Conference. [Összefoglalás a IV. Magyar Kardiovaszkuláris Konszenzus Konferencia ajánlásairól.] ' (2010 ) 8 Metabolizmus : 9 -12.

    • Search Google Scholar
  • Simonyi, G.: Obesity related diseases and their treatment. [Az elhízás kísérőbetegségei és kezelésük.]. Magyar Családorvosok Lapja, 2009, 3, 28–35. [Hungarian]

    Simonyi G. , 'Obesity related diseases and their treatment. [Az elhízás kísérőbetegségei és kezelésük.] ' (2009 ) 3 Magyar Családorvosok Lapja : 28 -35.

    • Search Google Scholar
  • Bedros, J. R., Simonyi, G.: Team work in obesitology. GP and specialist levels, centre. [Obezitológiai „team” munka. Háziorvosi szint, szakorvosi szint (centrum).] In: Császár, A., Bedros, J. R., Simonyi, G., et al. (eds.). Obezitás. Elmélet és klinikum. Teva Magyarország Zrt., Budapest, 2010, 370–371. [Hungarian]

    Simonyi G. , '', in Obezitás. Elmélet és klinikum , (2010 ) -.

  • Simonyi, G., Bedros, J. R.: Guidelines for treatment of obesity. Guidelines of the Hungarian Society of Obesitology and Exercise Therapy. [Az elhízás kezelésének szakmai és szervezeti irányelvei. A Magyar Obezitológiai és Mozgásterápiás Társaság irányelvei.]. Cardiometabolica Hungarica, 2008, 1 (Suppl. 1), 1–50. [Hungarian]

    Bedros J. R. , 'Guidelines for treatment of obesity. Guidelines of the Hungarian Society of Obesitology and Exercise Therapy. [Az elhízás kezelésének szakmai és szervezeti irányelvei. A Magyar Obezitológiai és Mozgásterápiás Társaság irányelvei.] ' (2008 ) 1 Cardiometabolica Hungarica : 1 -50.

    • Search Google Scholar
  • Kernan, W. N., Viscoli, C. M., Brass, L. M., et al.: Phenylpropanolamine and the risk of hemorrhagic stroke. N. Engl. J. Med., 2000, 343, 1826–1832.

    Brass L. M. , 'Phenylpropanolamine and the risk of hemorrhagic stroke ' (2000 ) 343 N. Engl. J. Med. : 1826 -1832.

    • Search Google Scholar
  • Dulloo, A. G., Seydoux, J., Girardier, L.: Peripheral mechanisms of thermogenesis induced by ephedrine and caffeine in brown adipose tissue. Int. J. Obes., 1991, 15, 317–326.

    Girardier L. , 'Peripheral mechanisms of thermogenesis induced by ephedrine and caffeine in brown adipose tissue ' (1991 ) 15 Int. J. Obes. : 317 -326.

    • Search Google Scholar
  • http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/DietarySupplements/ucm072997.htm (hozzáférés: 2012. január 16.)

  • Yanovski, S. Z., Yanovski, J. A.: Obesity. N. Engl. J. Med., 2002, 346, 591–602.

    Yanovski J. A. , 'Obesity ' (2002 ) 346 N. Engl. J. Med. : 591 -602.

  • FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen); [about 2 Screens]. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm179871.htm (letöltve 2012. január 16.)

  • Asakawa, A., Inui, A., Yuzuriha, H., et al.: Characterisation of the effects of panctreatic polypeptide in the regulation of energy balance. Gastroenterology, 2003, 124, 1325–1336.

    Yuzuriha H. , 'Characterisation of the effects of panctreatic polypeptide in the regulation of energy balance ' (2003 ) 124 Gastroenterology : 1325 -1336.

    • Search Google Scholar
  • Li, Z., Maglione, M., Tu, W., et al.: Meta-analysis: pharmacologic treatment of obesity. Ann. Intern. Med., 2005, 142, 532–546.

    Tu W. , 'Meta-analysis: pharmacologic treatment of obesity ' (2005 ) 142 Ann. Intern. Med. : 532 -546.

    • Search Google Scholar
  • James, W. P., Astrup, A., Finer, N., et al.: Effect of sibutramine on weight maintenance after weight loss: a randomized trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet, 2000, 356, 2119–2125.

    Finer N. , 'Effect of sibutramine on weight maintenance after weight loss: a randomized trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance ' (2000 ) 356 Lancet : 2119 -2125.

    • Search Google Scholar
  • James, W. P., Caterson, I. D., Coutinho, W., et al.: Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med., 2010, 363, 905–917.

    Coutinho W. , 'Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects ' (2010 ) 363 N. Engl. J. Med. : 905 -917.

    • Search Google Scholar
  • http://www.ema.europa.eu/pdfs/human/referral/sibutramine/3940810en.pdf (letöltve: 2012. január 16.)

  • Davidson, M. H., Hauptman, J., DiGirolamo, M., et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized trial. JAMA, 1999, 281, 235–242.

    DiGirolamo M. , 'Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized trial ' (1999 ) 281 JAMA : 235 -242.

    • Search Google Scholar
  • Maahs, D., de Serna, D. G., Kolotkin, R. L., et al.: Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr. Pract., 2006, 12, 18–28.

    Kolotkin R. L. , 'Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents ' (2006 ) 12 Endocr. Pract. : 18 -28.

    • Search Google Scholar
  • Kern, P. A., Ong, J. M., Saffari, B., et al.: The effects of weight loss on the activity and expression of adipose-tissue lipoprotein lipase in very obese humans. N. Engl. J. Med., 1990, 322, 1053–1059.

    Saffari B. , 'The effects of weight loss on the activity and expression of adipose-tissue lipoprotein lipase in very obese humans ' (1990 ) 322 N. Engl. J. Med. : 1053 -1059.

    • Search Google Scholar
  • Sjöström, L., Rissanen, A., Andersen, T., et al.: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet, 1998, 352, 167–172.

    Andersen T. , 'Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group ' (1998 ) 352 Lancet : 167 -172.

    • Search Google Scholar
  • Audikovszky, M., Pados, Gy., Seres, I., et al.: Orlistat increases serum paraoxonase activity in obese patients. Nutr. Metab. Cardiovasc. Dis., 2007, 17, 268–273.

    Seres I. , 'Orlistat increases serum paraoxonase activity in obese patients ' (2007 ) 17 Nutr. Metab. Cardiovasc. Dis. : 268 -273.

    • Search Google Scholar
  • Togerson, J. S., Hauptmann, J., Boldrin, M. N., et al.: XENIcal in the Prevention of Diabetes in the Obese Subjects (XENDOS) Study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 2004, 27, 155–161.

    Boldrin M. N. , 'XENIcal in the Prevention of Diabetes in the Obese Subjects (XENDOS) Study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients ' (2004 ) 27 Diabetes Care : 155 -161.

    • Search Google Scholar
  • Bryson, A., Dunk, C.: Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers. Br. J. Clin. Pharmacol., 2009, 67, 309–315.

    Dunk C. , 'Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers ' (2009 ) 67 Br. J. Clin. Pharmacol. : 309 -315.

    • Search Google Scholar
  • Hauner, H., Petzinna, D., Sommerauer, B., et al.: Effect of acarbose on weight maintenance after dietary weight loss in obese subjects. Diabetes Obes. Metab., 2001, 3, 423–427.

    Sommerauer B. , 'Effect of acarbose on weight maintenance after dietary weight loss in obese subjects ' (2001 ) 3 Diabetes Obes. Metab. : 423 -427.

    • Search Google Scholar
  • Knowler, W. C., Barrett-Connor, E., Fowler, S. E., et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med., 2002, 346, 393–403.

    Fowler S. E. , 'Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin ' (2002 ) 346 N. Engl. J. Med. : 393 -403.

    • Search Google Scholar
  • Pagotto, U., Pasquali, R.: Fighting obesity and associated risk factors by antagonizing cannabinoid type 1 receptors. Lancet, 2005, 365, 1363–1364.

    Pasquali R. , 'Fighting obesity and associated risk factors by antagonizing cannabinoid type 1 receptors ' (2005 ) 365 Lancet : 1363 -1364.

    • Search Google Scholar
  • Pi-Sunye, F. X., Arrone, L. J., Heshmati, H. M., et al.: Effect of rimonabant, a cannabinoid-1-receptor blocker on weight and cardiometabolic risk factors in overweight or obese patients. JAMA, 2006, 295, 761–775.

    Heshmati H. M. , 'Effect of rimonabant, a cannabinoid-1-receptor blocker on weight and cardiometabolic risk factors in overweight or obese patients ' (2006 ) 295 JAMA : 761 -775.

    • Search Google Scholar
  • http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-fdabackgrounder.pdf . (hozzáférés: 2012. január 16.)

  • http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000666/WC500021286.pdf (hozzáférés: 2012. január 16.)

  • Fluoxetine (Prozac) and other drugs for treatment of obesity. Med. Lett. Drugs Ther., 1994, 36, 107–108.

  • Bray, G. A., Hollander, P., Klein, S., et al.: A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res., 2003, 11, 722–733.

    Klein S. , 'A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity ' (2003 ) 11 Obes. Res. : 722 -733.

    • Search Google Scholar
  • McElroy, S. L., Guerdjikova, A. I., Martens, B., et al.: Role of antiepileptic drugs in the management of eating disorders. CNS Drugs, 2009, 23, 139–156.

    Martens B. , 'Role of antiepileptic drugs in the management of eating disorders ' (2009 ) 23 CNS Drugs : 139 -156.

    • Search Google Scholar
  • Bongioanni, P., Reali, C., Sogos, V.: Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst. Rev., 2004, 3, CD004302.

    Sogos V. , 'Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease ' (2004 ) 3 Cochrane Database Syst. Rev. : CD004302 -.

    • Search Google Scholar
  • Lambert, P. D., Anderson, K. D., Sleeman, M. W., et al.: Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc. Natl. Acad. Sci. USA, 2001, 98, 4652–4657.

    Sleeman M. W. , 'Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity ' (2001 ) 98 Proc. Natl. Acad. Sci. USA : 4652 -4657.

    • Search Google Scholar
  • Matthews, V. B., Febbraio, M. A.: CNTF: a target therapeutic for obesity-related metabolic disease? J. Mol. Med., 2008, 86, 353–361.

    Febbraio M. A. , 'CNTF: a target therapeutic for obesity-related metabolic disease? ' (2008 ) 86 J. Mol. Med. : 353 -361.

    • Search Google Scholar
  • Considine, R. V., Sinha, M. K., Heiman, M. L., et al.: Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med., 1996, 334, 292–295.

    Heiman M. L. , 'Serum immunoreactive-leptin concentrations in normal-weight and obese humans ' (1996 ) 334 N. Engl. J. Med. : 292 -295.

    • Search Google Scholar
  • Ahima, R. S., Flier, J. S.: Leptin. Annu. Rev. Physiol., 2000, 62, 413–437.

    Flier J. S. , 'Leptin ' (2000 ) 62 Annu. Rev. Physiol. : 413 -437.

  • Ravussin, E., Smith, S. R., Mitchell, J. A., et al.: Enhanced Weight Loss With Pramlintide/Metreleptin: An integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring), 2009, 17, 1736–1743.

    Mitchell J. A. , 'Enhanced Weight Loss With Pramlintide/Metreleptin: An integrated neurohormonal approach to obesity pharmacotherapy ' (2009 ) 17 Obesity (Silver Spring) : 1736 -1743.

    • Search Google Scholar
  • Dunican, K. C., Adams, N. M., Desilets, A. R.: The role of pramlintide for weight loss. Ann. Pharmacother., 2010, 44, 538–545.

    Desilets A. R. , 'The role of pramlintide for weight loss ' (2010 ) 44 Ann. Pharmacother. : 538 -545.

    • Search Google Scholar
  • Astrup, A., Rössner, S., Van Gaal, L., et al.: Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet, 2009, 374, 1606–1616.

    Van Gaal L. , 'Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study ' (2009 ) 374 Lancet : 1606 -1616.

    • Search Google Scholar
  • Rosenstock, J., Klaff, L. I., Schwartz, S., et al.: Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without prediabetes. Diabetes Care, 2010, 33, 1173–1175.

    Schwartz S. , 'Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without prediabetes ' (2010 ) 33 Diabetes Care : 1173 -1175.

    • Search Google Scholar
  • Wynne, K., Park, A. J., Small, C. J., et al.: Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes, 2005, 54, 2390–2395.

    Small C. J. , 'Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial ' (2005 ) 54 Diabetes : 2390 -2395.

    • Search Google Scholar
  • Gantz, I., Erondu, N., Mallick, M., et al.: Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J. Clin. Endocrinol. Metab., 2007, 92, 1754–1757.

    Mallick M. , 'Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults ' (2007 ) 92 J. Clin. Endocrinol. Metab. : 1754 -1757.

    • Search Google Scholar
  • Pados, Gy.: Up-to-date treatment of overweight and obesity. [A túlsúly és elhízás korszerű kezelése.] Zafír Press Kiadó, 2009. [Hungarian]

    Pados Gy. , '', in Up-to-date treatment of overweight and obesity. [A túlsúly és elhízás korszerű kezelése.] , (2009 ) -.

    • Search Google Scholar
  • Kiss, M.: Results of one-year weight-loss low-carb – high protein diet program in St. Imre Hospital. [Egyéves testsúlycsökkentő low-carb – high-protein diétás programban résztvevők paraméterei a Szent Imre Kórházban.]. Cardiometabolica Hungarica, 2011, 4 (Suppl. 3). In press. [Hungarian]

  • Gharib, H., Tuttle, R. M., Baskin, H. J., et al.: Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J. Clin. Endocrinol. Metab., 2005, 90, 581–585.

    Baskin H. J. , 'Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society ' (2005 ) 90 J. Clin. Endocrinol. Metab. : 581 -585.

    • Search Google Scholar
  • Celi, F. S., Zemskova, M., Linderman, J. D. et al.: Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine. J. Clin. Endocrinol. Metab., 2011, 96, 3466–3474.

    Linderman J. D. , 'Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine ' (2011 ) 96 J. Clin. Endocrinol. Metab. : 3466 -3474.

    • Search Google Scholar
  • Escobar-Morreale, H. F., Botella-Carretero, J. I., Escobar del Rey, F., et al.: REVIEW: Treatment of hypothyroidism with combinations of levothyroxine plus liothyronine. J. Clin. Endocrinol. Metab., 2005, 90, 4946–4954.

    Escobar del Rey F. , 'REVIEW: Treatment of hypothyroidism with combinations of levothyroxine plus liothyronine ' (2005 ) 90 J. Clin. Endocrinol. Metab. : 4946 -4954.

    • Search Google Scholar
  • Damiani, D.: Growth hormone usage in Prader-Willi syndrome. Arq. Bras. Endocrinol. Metabol., 2008, 52, 833–838.

    Damiani D. , 'Growth hormone usage in Prader-Willi syndrome ' (2008 ) 52 Arq. Bras. Endocrinol. Metabol. : 833 -838.

    • Search Google Scholar
  • Heffernan, M. A., Jiang, W. J., Thorburn, A. W., et al.: Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am. J. Physiol. Endocrinol. Metab., 2000, 279, E501–E507.

    Thorburn A. W. , 'Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism ' (2000 ) 279 Am. J. Physiol. Endocrinol. Metab. : E501 -E507.

    • Search Google Scholar
  • Lovejoy, J. C., Bray, G. A., Greeson, C. S., et al.: Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men. Int. J. Obes. Relat. Metab. Disord., 1995, 19, 614–624.

    Greeson C. S. , 'Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men ' (1995 ) 19 Int. J. Obes. Relat. Metab. Disord. : 614 -624.

    • Search Google Scholar
  • Astrup, A., Madsbad, S., Breum, L., et al.: Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet, 2008, 372, 1906–1913.

    Breum L. , 'Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial ' (2008 ) 372 Lancet : 1906 -1913.

    • Search Google Scholar
  • Hallschmid, M., Smolnik, R., McGregor, G., et al.: Brief report: overweight humans are resistant to the weight-reducing effects of melanocortin. J. Clin. Endocrinol. Metab., 2006, 91, 522–525.

    McGregor G. , 'Brief report: overweight humans are resistant to the weight-reducing effects of melanocortin ' (2006 ) 91 J. Clin. Endocrinol. Metab. : 522 -525.

    • Search Google Scholar
  • http://www.accessdata.fda.gov/scripts/fcn/gras_notices/707728A.PDF (hozzáférés: 2012. január 16.)

  • Nomura, S., Sakamaki, S., Hongu, M., et al.: Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J. Med. Chem., 2010, 53, 6355–6360.

    Hongu M. , 'Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus ' (2010 ) 53 J. Med. Chem. : 6355 -6360.

    • Search Google Scholar
  • Meng, W., Ellsworth, B. A., Nirschl, A. A., et al.: Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 2008, 51, 1145–1149.

    Nirschl A. A. , 'Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes ' (2008 ) 51 J. Med. Chem. : 1145 -1149.

    • Search Google Scholar
  • Bloomgarden, Z. T.: Gestational diabetes mellitus and obesity. Diabetes Care, 2010, 33, e60–e65.

    Bloomgarden Z. T. , 'Gestational diabetes mellitus and obesity ' (2010 ) 33 Diabetes Care : e60 -e65.

    • Search Google Scholar
  • Aronne, L. J., Halseth, A. E., Burns, C. M., et al.: Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity (Silver Spring), 2010, 18, 1739–1746.

    Burns C. M. , 'Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial ' (2010 ) 18 Obesity (Silver Spring) : 1739 -1746.

    • Search Google Scholar